News

Article section 1 of 1.

Mar 26, 2012

Researchers who investigated the connection between chronic cerebrospinal venous insufficiency (a reported condition characterized as a blockage in the veins that drain blood from the brain and spinal cord and returns it to the heart) and multiple sclerosis indicate that a minimally invasive endovascular treatment for CCSVI, is safe and may produce "significant," short-term improvement in physical- and mental health-related quality of life in individuals with multiple sclerosis. These findings were presented at the Society of Interventional Radiology's 37th Annual Scientific Meeting in San Francisco, California.

An estimated 400,000 people in the United States with multiple sclerosis—generally thought of as an incurable, disabling neurologic disease—may find hope that symptom relief is possible. Multiple sclerosis is typically treated with disease-modifying drugs, which modulate or suppress the immune response believed to be central in the progression of the disease.

"Traditional theories surrounding treatment for multiple sclerosis in large part focus on autoimmune causes for brain pathology and neurologic symptoms. Based on this, treatment has been predominantly medications by mouth or injection," stated Kenneth Mandato MD, an interventional radiologist at Albany Medical Center in Albany, New York. "Interventional radiologists, pioneers in the field of minimally invasive therapies, have been performing an endovascular therapy called angioplasty for years, to treat blocked or narrowed arteries and veins. We have been using angioplasty to open jugular and azygos veins in the neck and chest respectively to improve blood flow in people with MS. On follow-up, we have seen many of these individuals report significant symptom relief," he added.

Classifications within a diagnosis of multiple sclerosis include primary progressive, which means a gradually progressive disease without remission; relapsing remitting, which demonstrates acute attacks with intervals of slow improvements in symptoms; secondary progressive, where a disease that was once relapsing remitting is now slowly progressing. Multiple sclerosis subtypes within the Albany study group included 96 individuals with relapsing remitting, 66 with secondary progressive, and 30 with primary progressive. The study population included those who underwent angioplasty alone and 3 who underwent angioplasty with a stent (a tiny mesh tube used to hold the vessel open) placement.

"Results of the study were quite exciting and promising," stated Mandato. "We can attest to significant physical improvements reported in greater than 75% of those with relapsing remitting and primary progressive forms of multiple sclerosis. Additionally, mental health scores improved in greater than 70% of individuals studied. People with secondary progressive multiple sclerosis showed statistically significant improvements in both physical and mental health scores at a rate of 59% and 50%, respectively," he added.

"During a 4-month period, we treated 213 individuals. One hundred ninety-two of these patients (72 men, 141 women; average age 49 years) responded to a standard questionnaire that evaluated key quality of life components including changes in physical abilities, health perception, energy/fatigue, sexual function, emotional well-being, cognition, and pain," explained Meridith J Englander MD, also an interventional radiologist at Albany Medical Center and one of the study's co-authors. "We ultimately broke this data down into physical and mental health scores for each person, and found improvement in both components of quality of life," she added. "In addition, we found a trend that patients undergoing this treatment more than 10 years after diagnosis did not respond as well as those with a more recent diagnosis."

"To address the needs and concerns of those with MS who feel they cannot wait until definitive studies are completed, many doctors are currently offering treatments with the hope of helping individuals with hard-to-manage symptoms of MS," said Mandato. "Physicians who perform these treatments hope that this work will provide insights into the design of a prospective, randomized trial that is needed to rigorously evaluate the role of this treatment in MS," he added

"As we are still early in fully understanding the condition and its relation to treatment of CCSVI, it is our hope that future double-blinded prospective studies will be performed to further assess the durability of these results," said Mandato.